Pharmacokinetics and Pharmacodynamics Practice Questions

Q: Which of the following does not penetrate intact skin?

Dexmedetomidine. ***Dexmedetomidine*** - **Dexmedetomidine** is primarily administered intravenously as a continuous infusion for sedation and analgesia, as its molecular structure and properties do not allow for significant transdermal absorption. - While some research explores its transdermal delivery, it is **not considered to penetrate intact skin effectively** for therapeutic use through this route in current clinical practice. *Nitroglycerin* - **Nitroglycerin** patches and ointments are commonly used for the transdermal delivery of the drug to treat anginal symptoms. - Its **lipophilic nature** and small molecular size allow it to readily penetrate the skin barrier and enter systemic circulation. *Clonidine* - **Clonidine** is available in transdermal patch formulations for the treatment of hypertension. - Its ability to penetrate intact skin allows for **sustained release** and systemic absorption, providing continuous blood pressure control. *Scopolamine* - **Scopolamine** is widely used in transdermal patches to prevent motion sickness. - Its **small molecular weight** and lipophilicity enable effective penetration through the skin.

Q: In case of cyanide poisoning, antidote of amyl nitrite is given. This is an example of:

Chemical antagonism. ***Chemical antagonism*** - Amyl nitrite functions by inducing the formation of **methemoglobin**, which has a higher affinity for **cyanide ions** than cytochrome c oxidase. - This effectively sequesters cyanide, rendering it unable to bind to and inhibit the **cytochrome oxidase enzyme**, thus preventing its toxic effects [3]. *Receptor antagonism* - This involves a drug binding to a **receptor** and blocking the action of an **agonist**, without activating the receptor itself [1], [2]. - Amyl nitrite does not exert its effect by binding to a specific receptor and blocking cyanide's action; instead, it directly interacts with cyanide itself. *Physical antagonism* - This type of antagonism involves a drug preventing another drug's action through a **physical property**, such as adsorption or chelation. - While there is an interaction, the formation of methemoglobin and its subsequent binding to cyanide is more precisely described as a chemical reaction rather than a simple physical interaction or adsorption. *Physiological antagonism* - This occurs when two drugs act on **different receptors** or pathways to produce **opposite physiological effects**. - Amyl nitrite does not produce an opposite physiological effect by acting on a different pathway; rather, it directly counteracts the chemical nature of cyanide.

Q: Which of the following drugs shown in the graph below has highest potency?

Drug A. ***Drug A*** - **Potency** is determined by the concentration (or dose) of a drug required to produce 50% of its maximal effect (**EC50** or **ED50**). On a dose-response curve, the drug shifted furthest to the **left** (requiring a lower dose) is the most potent. - Drug A reaches 50% of its maximum effect at the **lowest concentration** compared to Drugs B and C, indicating higher potency. *Drug B* - Drug B requires a **higher concentration** than Drug A to achieve 50% of its maximal effect, indicating it is less potent than Drug A. - While Drug B reaches the same maximal effect as Drug A, its dose-response curve is shifted to the **right** of Drug A's. *Both Drug A and Drug B* - Although both drugs reach the same **maximal efficacy**, their potencies differ significantly. - Drug A achieves this maximal effect at a much **lower dose** than Drug B. *Drug C* - Drug C not only requires a **higher concentration** to reach its maximal effect but also exhibits a **lower maximal efficacy** compared to Drugs A and B. - Both its potency and efficacy are **lower** than those of Drug A.

Q: Longest acting local anesthetic agent is -

Bupivacaine. ***Bupivacaine*** - **Bupivacaine** is the **longest-acting local anesthetic** in common clinical use, with a duration of action of **2-9 hours** (up to 12+ hours with epinephrine). - Its prolonged effect is due to **high lipid solubility** and **extensive protein binding** (95%), allowing it to remain at the nerve site for an extended period. - Widely used for **epidural anesthesia**, **spinal anesthesia**, and **peripheral nerve blocks** requiring prolonged analgesia. *Dibucaine* - Dibucaine, while theoretically long-acting, is **rarely used clinically** in modern practice. - Primarily known as a **research tool** for testing plasma pseudocholinesterase activity (dibucaine number test). - Not a standard answer for competitive medical examinations. *Procaine* - **Procaine** is a **short-acting** local anesthetic (30-60 minutes), primarily used for infiltration. - Its rapid metabolism by **plasma pseudocholinesterase** limits its duration of action. *Lidocaine* - **Lidocaine** is an **intermediate-acting** local anesthetic (1-3 hours), widely used for various procedures due to its rapid onset and moderate duration. - Its duration is significantly shorter than bupivacaine.

Q: Low apparent volume of distribution of drug indicates that:

Drug is not extensively distributed to tissue. ***Drug is not extensively distributed to tissue*** - A **low apparent volume of distribution (Vd)** suggests that the drug primarily remains in the **vascular compartment**. - This indicates **minimal binding to peripheral tissues** and less distribution into extravascular spaces. *Drug has low bioavailability* - **Bioavailability** refers to the fraction of an administered drug that reaches the **systemic circulation unchanged**. - While related to drug disposition, a low Vd does not directly imply low bioavailability; a drug can have high bioavailability but remain largely in the blood. *Drug has low efficacy* - **Efficacy** is the maximum effect a drug can produce regardless of the dose. - Vd relates to drug distribution, not its pharmacological effect or **intrinsic activity** at its target. *Drug has low half life* - The **half-life** of a drug is determined by its **volume of distribution (Vd)** and **clearance (CL)** (t½ = 0.693 × Vd / CL). - While a low Vd can contribute to a shorter half-life if clearance is high, Vd alone does not solely determine half-life; clearance also plays a significant role.

Q: Duration of action of proparacaine:

20min. ***20min*** - **Proparacaine** is a **topical ophthalmic anesthetic** widely used for procedures like **tonometry**, **foreign body removal**, and **minor ocular surgeries**. - Its **duration of action** is typically **15-20 minutes**, making **20 minutes** the most accurate answer representing the standard effective duration. - This duration provides adequate anesthesia for most diagnostic and minor procedural needs in ophthalmology. *10min* - While proparacaine may provide some anesthetic effect at **10 minutes**, this represents the **lower end** of its duration and is **not the standard cited duration** in medical literature. - Most authoritative sources cite the duration as **15-20 minutes** rather than 10 minutes. - Relying on only 10 minutes of action would be insufficient for many ophthalmic procedures. *2min* - A duration of **2 minutes** is far too short for proparacaine's clinical applications. - Although proparacaine has a **rapid onset** (20-30 seconds), its anesthetic effect persists much longer. - This duration would be inadequate for even the briefest procedures. *5min* - **5 minutes** significantly underestimates proparacaine's duration of action. - This would not provide sufficient anesthesia for most diagnostic or therapeutic ophthalmic procedures. - Clinical practice and pharmacological data support a much longer duration.

Q: G-protein coupled receptor that does not act through opening of potassium channels is:

Angiotensin 1 receptor. ***Angiotensin 1 receptor*** - The **angiotensin 1 receptor (AT1R)** is a **Gq-coupled receptor** that primarily activates the **phospholipase C (PLC)** pathway, leading to increased intracellular **calcium** and **IP3/DAG** signaling. - Its activation mediates vasoconstriction, aldosterone release, and cardiac hypertrophy, none of which involve direct opening of potassium channels. *Dopamine D2 receptor* - **Dopamine D2 receptors** are **Gi/o-coupled receptors** that inhibit adenylyl cyclase and **open potassium channels**, leading to **hyperpolarization** and reduced neuronal excitability. - This action contributes to its **antipsychotic** and **motor control** effects. *Muscarinic M2 receptor* - **Muscarinic M2 receptors** are **Gi/o-coupled receptors** found in the heart that cause **bradycardia** by activating **acetylcholine-gated inwardly rectifying potassium (GIRK) channels**, leading to hyperpolarization. - They also inhibit adenylyl cyclase, reducing cAMP levels and decreasing heart rate and contractility. *Serotonin 5 HT 1 receptor* - **Serotonin 5-HT1 receptors** (e.g., 5-HT1A) are **Gi/o-coupled receptors** that, upon activation, **increase potassium conductance** (hyperpolarization) and inhibit adenylyl cyclase. - This leads to a reduction in neuronal firing and is implicated in the anxiolytic and antidepressant effects of these receptors.

Q: All are true for cytochrome P450 enzymes EXCEPT:

Synthesize amino acids. ***Synthesize amino acids*** - Cytochrome P450 enzymes are primarily involved in the **metabolism of xenobiotics** and endogenous compounds, not in the synthesis of amino acids. - **Amino acid synthesis** occurs through different metabolic pathways involving various enzymes distinct from the cytochrome P450 system. *Involved in drug metabolism* - Cytochrome P450 enzymes are a major group of enzymes crucial for the **biotransformation of numerous drugs** and other foreign compounds. - They typically catalyze **oxidation reactions**, preparing drugs for excretion. *Present mainly in the liver* - While present in many tissues, the **highest concentration and diversity** of cytochrome P450 enzymes are found in the **liver**, which is the primary site of drug metabolism. - They are also found in the gastrointestinal tract, kidney, lung, and brain, but to a lesser extent. *Part of Phase I metabolism* - Cytochrome P450 enzymes are the **principal enzymes responsible for Phase I reactions** in drug metabolism. - **Phase I metabolism** generally involves reduction, oxidation, or hydrolysis reactions to introduce polar groups to the drug molecule.

Q: What is the primary role of Cytochrome P450 enzymes in the liver?

Oxidation of drugs. ***Oxidation of drugs*** - **Cytochrome P450 enzymes** are a superfamily of monooxygenases that primarily catalyze the **oxidation of various endogenous and exogenous substrates**, including drugs [1, 2]. - This oxidative metabolism is a key step in detoxification and elimination of foreign compounds from the body [1]. *Lipid transport* - **Lipid transport** is primarily facilitated by **lipoproteins** and specific **transport proteins** in the blood and within cells. - While P450 enzymes can metabolize some lipids, their primary role is not in lipid transport [2]. *Carbohydrate synthesis* - **Carbohydrate synthesis**, or **gluconeogenesis**, is mainly carried out by enzymes such as **pyruvate carboxylase** and **fructose-1,6-bisphosphatase**. - Cytochrome P450 enzymes do not play a direct role in the synthesis of carbohydrates. *Protein degradation* - **Protein degradation** is largely mediated by the **ubiquitin-proteasome system** and **lysosomal pathways**. - Cytochrome P450 enzymes are not directly involved in breaking down proteins into smaller peptides or amino acids.

Question 1

Which of the following does not penetrate intact skin?

Accepted Answer

Dexmedetomidine

Answer

Nitroglycerine

Answer

Clonidine

Answer

Scopolamine

Question 2

In case of cyanide poisoning, antidote of amyl nitrite is given. This is an example of:

Accepted Answer

Chemical antagonism

Answer

Receptor antagonism

Answer

Physical antagonism

Answer

Physiological antagonism

Question 3

Which of the following drugs shown in the graph below has highest potency?

Accepted Answer

Drug A

Answer

Drug B

Answer

Both Drug A and Drug B

Answer

Drug C

Question 4

Longest acting local anesthetic agent is -

Accepted Answer

Bupivacaine

Answer

Procaine

Answer

Lidocaine

Answer

Dibucaine

Question 5

Low apparent volume of distribution of drug indicates that:

Accepted Answer

Drug is not extensively distributed to tissue

Answer

Drug has low bioavailability

Answer

Drug has low efficacy

Answer

Drug has low half life

Question 6

Duration of action of proparacaine:

Accepted Answer

20min

Answer

2min

Answer

5min

Answer

10min

Question 7

G-protein coupled receptor that does not act through opening of potassium channels is:

Accepted Answer

Angiotensin 1 receptor

Answer

Dopamine D2 receptor

Answer

Muscarinic M2 receptor

Answer

Serotonin 5 HT 1 receptor

Question 8

All are true for cytochrome P450 enzymes EXCEPT:

Accepted Answer

Synthesize amino acids

Answer

Involved in drug metabolism

Answer

Present mainly in the liver

Answer

Part of Phase I metabolism

Question 9

What is the primary role of Cytochrome P450 enzymes in the liver?

Accepted Answer

Oxidation of drugs

Answer

Lipid transport

Answer

Carbohydrate synthesis

Answer

Protein degradation

Question 10

Which of the following statements is true regarding zero-order kinetics?

Accepted Answer

Follows a constant rate of elimination regardless of concentration.

Answer

Commonly seen in therapeutic doses of most drugs.

Answer

Rate of elimination depends on drug concentration.

Answer

Occurs only at subtherapeutic doses of drugs.

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?